Open AccessDipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
Author(s) -
Yabe Daisuke,
Seino Yutaka
Publication year - 2014
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12229
Subject(s) - medicine , hypoglycemia , sitagliptin , type 2 diabetes , incretin , diabetes mellitus , glycated hemoglobin , dipeptidyl peptidase 4 , type 2 diabetes mellitus , endocrinology , insulin , pharmacology
Although DPP‐4 inhibitors alone have little hypoglycemia risk, cases of severe hypoglycemia were reported among patients who were with SU secondary failure and received add‐on of DPP‐4 inhibitors. The recommendation to reduce SU dosages at the time of DPP‐4 inhibitor add‐on successfully prevented cases of sever hypoglycemia, but underlying mechanisms of hypoglycemia in SU secondary failure remained to be addressed